SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-077203
Filing Date
2021-06-04
Accepted
2021-06-04 17:48:44
Documents
2
Period of Report
2021-06-02

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2118134-6_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2118134-6_3seq1.xml 3 1582
2 EXHIBIT 24.1 tm2118134d6_ex24-1.htm EX-24.1 7425
  Complete submission text file 0001104659-21-077203.txt   10464
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Issuer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 3737 MARKET STREET, SUITE 1300 PHILADELPHIA PA 19104
Business Address
Dalton Lisa (Reporting) CIK: 0001732196 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37558 | Film No.: 21997644